Skip to content
The Policy VaultThe Policy Vault

Sandostatin (octreotide acetate)United Healthcare

Bleeding gastroesophageal varices associated with liver disease

Initial criteria

  • Diagnosis of bleeding gastroesophageal varices associated with liver disease

Reauthorization criteria

  • Documentation of positive clinical response to Sandostatin therapy

Approval duration

12 months